Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal Oniris

Home page

BabH: monitoring human Babesiosis in France and characterization of the responsible agents

BabH
Human Babesiosis: a One Health approach, working in collaboration with the medical community

Babesiosis is a tick-borne disease caused by the development of parasites of the genus Babesia in red blood cells1. Frequent and of moderate severity in the USA, symptomatic babesiosis is rare in Europe, but fatal in immuno-compromised individuals2. Humans are an "accidental" host and zoonotic species have domestic animals (cattle) or wild animals (micro-mammals, deer) as natural hosts3,4. As a research laboratory working on these species and their epidemiology for more than 20 years, we maintain a watch on humans in order to refine diagnostic methods and knowledge on these zoonotic agents5, but also to detect the emergence or establishment of newly introduced species.
Our work shows a high seroprevalence in humans, indicating frequent exposure to the parasite, but the actual presence of Babesia (molecular detection or isolation in in vitro culture) remains rare. In most cases, immuno-competent humans are able to eliminate it naturally. Rare cases of often asymptomatic carriage exist, and only B. divergens, a species of bovine origin, has been detected.
We occasionally collaborate with the hospital environment when analyses for patients suspected of babesiosis are sent to us. We are in the process of characterizing at the molecular level a new species of zoonotic Babesia of group B. divergens6.

1 Jalovecka M, Hajdusek O, Sojka D, Kopacek P, Malandrin L. 2018. The Complexity of Piroplasms Life Cycles. Front Cell Infect Microbiol. 2018 8:248.

2 Lempereur L, Shiels B, Heyman P, Moreau E, Saegerman C, Losson B, Malandrin L. 2015. A retrospective serological survey on human babesiosis in Belgium. Clin Microbiol Infect. 21(1):96.e1-7.

3 Becker CA, Bouju-Albert A, Jouglin M, Chauvin A, Malandrin L. 2009. Natural transmission of zoonotic Babesia spp. by Ixodes ricinus ticks. Emerg Infect Dis. 15(2):320-2.

4 Jouglin M, Perez G, Butet A, Malandrin L, Bastian S. 2017. Low prevalence of zoonotic Babesia in small mammals and Ixodes ricinus in Brittany, France. Vet Parasitol. 2017 Apr 30;238:58-60.

5 Jouglin M., Bastian S., Abou-Bacar A., Ermanno C. De Briel D. Chauvin A. Malandrin L. , 2010. Babésiose humaine clinique et asymptomatique : intérêt et faisabilité d'une veille sanitaire. REID, 18-19 Nov 2010.

6 Martinot et al., 2011. Babesiosis in Immunocompetent Patients, Europe. Emerg. Inf. Dis. 17:114-116.

Contact person : laurence.malandrin@oniris-nantes.fr

Publications :

de Carné MC, Moussel F, Laurichesse JJ, Malandrin L, Perronne V. Human Babesiosis: report of a rare case. IDcases soumis.

Paleau A, Candolfi E, Souply L, De Briel D, Delarbre JM, Lipsker D, Jouglin M, Malandrin L, Hansmann Y, Martinot M. 2019. Human babesiosis in Alsace: a retrospective study (2005-2015). Med Mal Infect. Sep 20. pii: S0399-077X(18)30611-5. doi: 10.1016/j.medmal.2019.08.007.

postermini

Jouglin M., De La Cotte Nathalie, Bonsergent C., Bastian S., Malandrin L. 2018. La Babésiose humaine : bilan de 10 ans d'analyses. Med Mal Infect. 48:S112-S113. DOI 10.1016/j.medmal.2018.04.284.

Martinot M., Paleau A., Greigert V., Brunet J., Hansmann Y., Jouglin M., Souply L., Jaulhac B., De Briel D., Candolfi E. 2018. Babésiose en France et en Europe : une pathologie à redéfinir. Med Mal Infect. 48:S112. DOI 10.1016/j.medmal.2018.04.284.

International Colloquium

Bonsergent C., de la Cotte N., Jouglin M., de Carné MC., Perronne V., Malandrin L. 2019.
Human babesiosis : molecular characterization of a new etiological agent in the “B. divergens species complex”. International Symposium on Tick-borne pathogens and disease (ITPD), 8-11 Septembre 2019, Vienne, Autriche.

International Colloquium